Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elimusertib + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Elimusertib + pembrolizumab is a combination of two investigational drugs for the treatment of advanced solid tumors, specifically in patients with DNA damage response (DDR) deficiency. Elimusertib (BAY1895344) is an oral, highly selective inhibitor of the enzyme ATR kinase, which plays a key role in the DNA damage response and tumor cell survival. Pembrolizumab is an immune checkpoint inhibitor targeting programmed death-1 (PD-1) on T cells, enhancing immune-mediated tumor destruction. The combination is under investigation in phase 1b clinical trials for safety, dose optimization, pharmacokinetics and preliminary anti-tumor activity[1][2][3][4][9][10].
- Other names
- elimusertib + pembrolizumabBAY1895344 + pembrolizumab
02
Targets
ATR (ATR serine/threonine kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on elimusertib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elimusertib + pembrolizumab.